Method for measuring antigens or antibodies in biological fluids using ligand labeled antigens or ligand labeled antibodies

• US 4,778,751 A
• Filed: 05/12/1986
• Issued: 10/18/1988
• Est. Priority Date: 05/12/1986
• Status: Expired due to Term

• Current Assignee: Diagnostic Products Corp. (Siemens AG)
• Original Assignee: Diagnostic Products Corp. (Siemens AG)
• Inventors: Kasal, Charles A., Alaba, Olusola O., El Shami, A. Said
• Primary Examiner(s): Warden, Robert J.
• Assistant Examiner(s): Wagner, Richard
• Application Number:
  US06/862,123
• Time in Patent Office: 890 Days
• Field of Search: 435/7, 435/805, 436/501, 436/503, 436/504, 436/513, 436/527, 436/532, 436/538, 436/539, 436/541, 436/542, 436/823
• US Class Current: 435/7.5
• CPC Class Codes: G01N 33/531 Production of immunochemical test materials
• CPC Class Codes: G01N 33/538 by sorbent column, particles or resin strip , i.e. sorbent materials
• CPC Class Codes: G01N 33/54306 Solid-phase reaction mechanisms
• CPC Class Codes: G01N 33/548 Carbohydrates, e.g. dextran
• CPC Class Codes: Y10S 435/805 Test papers
• CPC Class Codes: Y10S 435/971 Capture of complex after antigen-antibody reaction
• CPC Class Codes: Y10S 436/823 Immunogenic carrier or carrier per se

Abstract

The method of measuring circulating antigens or antibodies by using a ligand labeled specific antigen or ligand labeled specific antibody chemically attached to a soluble matrix or backbone, a differently labeled anti-antigen or anti-antibody and a solid phase anti-ligand directed at the ligand attached to the specific antigen or specific antibody. This is achieved by either one or two analytical schemes:

(a) Reacting a patient sample with a ligand labeled specific antigen or a ligand labeled specific antibody in the liquid phase in the presence of a differently labeled specific anti-antigen or labeled specific anti-antibody. This immunological complex is reacted with an immobilized anti-ligand on a solid support which is directed against the ligand attached to the specific antigen or antibody through the liquid matrix. Subsequently the solid phase is washed and checked for the label on the anti-antigen or anti-antibody which is directly proportional to the concentration of specific antigen or antibody.

(b) Reacting a patient sample with the ligand labeled specific antigen or a ligand labeled specific antibody in the liquid phase, then contacting said liquid phase with an immobilized anti-ligand on a solid support; washing the solid support and reacting it with a differently labeled anti-antigen or anti-antibody. This is followed by re-washing of the solid support and checking for the presence of the label attached to the anti-antigen or anti-antibody which is directly proportional to the concentration of the specific antigen or antibody. The ligand is covalently attached to the specific antigen or antibody through a soluble liquid matrix or backbone to which the specific antigen or antibody has been chemically attached. This invention is applicable to a wide variety of antigen or antibody detection as described herein.

Claims

1. A method for measuring the level of an antigen (Ag₁), antibody (Ab₁) or hapten (H) in a liquid sample, which sequentially comprises:

(a) forming in a liquid phase reaction a soluble complex wherein said antigen (Ag₁), antibody (Ab₁) or hapten (H) is linked through, respectively, a specific antibody (Ab), antigen (Ag) or antihapten (Anti-H), to a matrix which is soluble in the liquid phase and carries a ligand (X), said matrix capable of being chemically attached to more than one specific antibody (Ab), antigen (Ag) or antihapten (Anti-H);

(b) forming an insolubilized complex comprising a solid support linked to the ligand (X) of said soluble complex through an anti-ligand (Y), the insolubilized complex carrying a label (Z) linked to the antigen (Ag₁) through an anti-antigen (Anti-Ag₁), to the antibody (Ab₁) through an anti-antibody (Anti-Ab₁) or to the hapten (H);

(c) washing the insolubilized complex; and

(d) observing the washed insolubilized complex for the presence of the label (Z) wherein the presence of the label (Z) is an indication of the level of said antigen (Ag₁), antibody (Ab₁) or hapten (H) in said sample.

2. A method according to claim 1 wherein the label (Z) is an enzymatic label, a radioactive label, a fluorescent label, chemiluminescent label or a bioluminescent label.

3. A method according to claim 1 or 2 wherein the matrix is a soluble carbohydrate with a molecular mass of from 6,000 to 80,000 daltons or a Ficoll with a molecular mass of from 70,000 to 400,000 daltons.

4. A method according to claim 3 wherein the matrix is a dextran.

5. A method according to claim 1 or 2 wherein the matrix is a soluble polymer or copolymer with a molecular mass of from 5,000 to 200,000 daltons.

6. A method according to claims 1 or 2 wherein the ligand (X) is covalently attached to the matrix through an amino acid copolymer.

7. A method according to claims 1 or 2 wherein the ligand (X) is avidin, the solid support is a tube coated with avidin, and biotin is added to effect the immobilization of the soluble complex onto the avidin coated tube.

8. A method according to claims 1 or 4 wherein the ligand (X) is biotin, the solid support is a tube coated with an anti-avidin antibody, and avidin is added to effect the immobilization of the soluble complex onto the anti-avidin antibody coated tube.

9. A method according to any one of claims 1 to 6 wherein the ligand (X) is biotin, the solid support is a coated tube coated with biotinylated protein, and avidin is added to effect the immobilization of the soluble complex onto the biotinylated protein coated tube.

10. A method according to claims 1 or 2 wherein the ligand (X) is selected from hapten, avidin and bovine serum albumin, and the anti-ligand (Y) is selected from anti-hapten, anti-avidin and anti-bovine serum albumin, respectively, and wherein the hapten is selected from biotin, fluoresceine and dinitrophenol, and the anti-hapten is selected from avidin or anti-biotin, anti-fluoresceine and anti-dinitrophenol, respectively.

11. A method according to claims 1 or 2 wherein the ligand (X) is covalently attached to the matrix, and the specific antibody (Ab) or antigen (Ag) is chemically attached to the matrix.

12. A method according to claims 1 or 2 wherein the sample contains an antigen (Ag₁) or antibody (Ab₁), the soluble complex is formed by reacting the sample in the liquid phase with said matrix carrying ligand (X) and specific antibody (Ab) or antigen (Ag) in the presence of an anti-antigen (Anti-Ag₁) or anti-antibody (Anti-Ab₁) labelled with said label (Z) to form said soluble complex, reacting this soluble complex with immobilized anti-ligand (Y) on a solid support to form an insolubilized complex, washing the insolubilized complex, and observing the washed insolubilized complex for the label (Z) on the anti-antigen (Anti-Ag₁) or anti-antibody (Anti-Ab₁).

13. A method according to claims 1 or 2 wherein the sample contains an antigen (Ag₁) or antibody (Ab₁), the soluble complex is formed by reacting the sample in the liquid phase with a said matrix carrying said ligand (X) and said specific antibody (Ab) or antigen (Ag), the insolubilized complex is formed by contacting said soluble complex with immobilized anti-ligand (Y) on a solid support to form an insolubilized complex, washing the insolubilized complex, reacting it with an anti-antigen (Anti-Ag₁) or anti-antibody (Anti-Ab₁) labelled with said label (Z), rewashing the resulting insolubilized complex, and observing the washed insolubilized complex for the presence of the label attached to the anti-antigen (Anti-Ag₁), or anti-antibody (Anti-Ab₁).

14. A method according to claims 1 or 2 wherein the sample contains a hapten (H), the soluble complex is formed by reacting the sample in the liquid phase with a said matrix carrying ligand (X) and a specific anti-hapten (Anti-H) in the presence of a labeled hapten probe (H-Z), allowing competitive binding to occur between the hapten (H) in the sample and the labeled hapten probe (H-Z) for anti-hapten (Anti-H) binding sites on the matrix, reacting the resulting soluble complex with immobilized anti-ligand (Y) on a solid support to form an insolubilized complex, washing insolubilized complex, and observing the washed insolubilized complex for the label (Z).